Urtė Fultinavičiūtė
Reporter
Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.
Latest From Urtė Fultinavičiūtė
Lilly And EVA Pharma Sign Voluntary License Deal For Baricitinib In Africa
Eli Lilly will provide a know-how manufacturing guide to EVA Pharma, as it prepares to manufacture and sell baricitinib by 2026.
Lupin Launches Higher Mirabegron Dose ‘At-Risk’
Lupin and Zydus have established a two-player market for their generic versions of mirabegron, while patent litigation with originator Astellas continues on.
China Suspends Dr Reddy’s ADHD Drug Due To ‘Serious Defects’
China’s NMPA import ban on a Dr Reddy’s ADHD drug due to manufacturing issues has left the firm calculating the monetary impact.
Lilly And EVA Pharma Sign Voluntary License Deal For Baricitinib In Africa
Eli Lilly will provide a know-how manufacturing guide to EVA Pharma, as it prepares to manufacture and sell baricitinib by 2026.
Lupin Marks Its Second Canadian Biosimilar Approval With Pegfilgrastim
With several other competitors with pegfilgrastim biosimilars already on the Canadian market, Lupin celebrates its second regional approval.
Sunshine Biopharma Expands Its Generics Portfolio In Canada
After adding nine generics to its portfolio, Sunshine Biopharma prepares for more launches in the next year to strengthen its presence in Canada.